Form 4: Dyne Therapeutics Executive Sells Shares to Cover Tax Obligations

Richard William Scalzo, SVP, Head of Finance & Admin. at Dyne Therapeutics, sold 2,488 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Summary

• Richard William Scalzo, a senior executive at Dyne Therapeutics, sold 2,488 shares of the company's common stock on February 18, 2025.
• The sale was executed at a weighted average price of $13.95 per share, with individual transactions ranging from $13.95 to $14.05.
• This transaction was to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) granted on November 15, 2023.
• Following the transaction, Scalzo directly owns 124,590 shares of Dyne Therapeutics, which includes 114,079 unvested RSUs.
• The sale was conducted under a pre-arranged plan (Rule 10b5-1) to satisfy tax obligations.

Sentiment

Score: 5

Explanation: Neutral sentiment as the transaction is a routine sale to cover tax obligations and doesn't reflect a change in the executive's outlook on the company.

Future Outlook

There is no future outlook information provided in this document.

Industry Context

This is a routine transaction for executives to cover tax obligations related to equity compensation. It is common practice and generally doesn't indicate a change in the executive's confidence in the company.

Stakeholder Impact

• The sale of shares by an executive could have a minor negative impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates

Keywords

Dyne Therapeutics, Richard Scalzo, stock sale, Form 4, insider trading, Rule 10b5-1, RSUs, tax obligations, DYN